BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of Prostate Specific Membrane
Antigen (PSMA ADC), as well as its safety and side effects for patients with advanced brain
tumors. This study will also study how your body metabolizes (breaks down) PSMA ADC.
Phase:
Phase 2
Details
Lead Sponsor:
Heinrich Elinzano, MD
Collaborators:
Progenics Pharmaceuticals, Inc. Rhode Island Hospital University of Texas